
ASX biotechs join global race for cell therapy breakthroughs
ASX biotechs are working to advance cell therapies. Pic: Getty Images ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric …